MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijbiomac.2026.154804

Медицинская библиотека · International journal of biological macromolecules · 2026

Multivalent protein nanocages improve the safety profile of cluster of differentiation 47 checkpoint blockade.

Ahn Wonkyung, Kim Seonghyun, Lee Yeram, Chae Jinkyoung, Park Dongsu, Chang Ki Hwan, Lee Pedro, Cho Sungkuk, Kim Taeerk, Kim In-San, Nam Gi-Hoon, Lee Eun Jung

СтатьяПеревод пока не подготовлен

Аннотация

Protein-based nanocages are emerging as promising platforms for next-generation medicine because of their programmable architecture, biocompatibility, and capacity for functional integration. In the field of immunotherapy, these properties offer a structural basis for overcoming key limitations of conventional antibody-based therapeutics, where potent checkpoint blockade activity is often accompanied by systemic toxicity. Here, we demonstrate that a ferritin-signal regulatory protein alpha (SIRPα) protein nanocage maintains the therapeutic function of cluster of differentiation 47 (CD47)-SIRPα blockade while reducing the hematologic liabilities associated with CD47-targeting monoclonal antibodies. Although the CD47-SIRPα axis is a compelling innate immune checkpoint target broadly implicated in tumor immune evasion, anti-CD47 antibodies have been limited by the widespread expression of CD47 on both tumor cells and normal erythrocytes, which can result in dose-limiting hematologic toxicity. By displaying multivalent SIRPα domains on a self-assembling ferritin scaffold, ferritin-SIRPα achieves CD47 engagement through a structurally distinct, Fc-independent nanocage architecture. In direct comparison with anti-CD47 antibody, ferritin-SIRPα showed no hemagglutination at equivalent or higher doses, preserved near-complete viability across diverse immune and hematopoietic cell types, and avoided the reduction in RBC counts observed with anti-CD47 antibody treatment in vivo. Ferritin-SIRPα induced macrophage-mediated tumor cell phagocytosis under single-agent conditions, with further enhancement observed upon combination with EGFR antibody-mediated opsonization, indicating that its innate immune engagement remains functionally intact. These findings demonstrate that multivalent protein nanocage architecture can decouple antitumor immune activity from erythrocyte-associated toxicity. Broadly, this study highlights the potential of protein nanocages as a versatile therapeutic platform for preserving functional efficacy while mitigating off-target adverse effects, offering a structural strategy that may help improve the therapeutic window of next-generation immunotherapies.

Для цитирования: Ahn Wonkyung, Kim Seonghyun, Lee Yeram, Chae Jinkyoung, Park Dongsu, Chang Ki Hwan, Lee Pedro, Cho Sungkuk, Kim Taeerk, Kim In-San, Nam Gi-Hoon, Lee Eun Jung. Multivalent protein nanocages improve the safety profile of cluster of differentiation 47 checkpoint blockade.. International journal of biological macromolecules. 2026. DOI: 10.1016/j.ijbiomac.2026.154804.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.